Invasive Fungal Infections in Lung Transplant Recipients Not Receiving Routine Systemic Antifungal Prophylaxis: 12-Year Experience at a University Lung Transplant Center

被引:14
作者
Pinney, Marlena F. [1 ]
Rosenberg, Amy F. [2 ]
Hampp, Christian [3 ]
Schain, Denise [4 ]
Akindipe, Olufemi [5 ]
Baz, Maher [5 ]
机构
[1] Orlando Reg Med Ctr Inc, Dept Pharm Serv, Orlando, FL 32806 USA
[2] Univ Florida, Dept Pharm Serv, Gainesville, FL USA
[3] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA
[4] Univ Florida, Coll Med, Div Infect Dis, Gainesville, FL USA
[5] Univ Florida, Coll Med, Div Pulm Crit Care & Sleep Med, Gainesville, FL USA
来源
PHARMACOTHERAPY | 2011年 / 31卷 / 06期
关键词
invasive fungal infections; Aspergillus infection; antifungal prophylaxis; lung transplant; ASPERGILLUS INFECTIONS; RISK-FACTORS; ITRACONAZOLE PROPHYLAXIS; VORICONAZOLE; MANAGEMENT;
D O I
10.1592/phco.31.6.537
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To determine the rate of invasive fungal infection among the lung transplant population at a center that does not provide routine systemic antifungal prophylaxis, and to compare that rate with rates currently reported in the literature. Design. Retrospective medical record review. Setting. University-affiliated lung transplant center. Patients. Two hundred forty-two adults without cystic fibrosis who underwent lung transplantation between March 1, 1994, and June 30, 2006. Measurements and Main Results. Patients were followed by the adult lung transplant service. Twenty-three cases of invasive fungal infections were identified in 22 patients, resulting in a 9.1% overall invasive fungal infection rate in our study population. Aspergillus infections were the most common type of fungal infection identified, occurring in 11(47.8%) of the 23 cases, with an overall rate of 4.5% (11/242 patients). Invasive fungal infections in lung transplant recipients have been reported in the literature at a rate 15-35%, with rates of Aspergillus infections reported as 3-15%. Conclusion. Despite the absence of routine systemic antifungal prophylaxis, the overall invasive fungal infection rate and the Aspergillus infection rate in these lung transplant recipients do not appear to be higher than the rates reported in the literature.
引用
收藏
页码:537 / 545
页数:9
相关论文
共 18 条
[1]   Candida pneumonia: What we know and what we don't [J].
Barkauskas C.E. ;
Perfect J.R. .
Current Fungal Infection Reports, 2009, 3 (1) :21-31
[2]   Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness [J].
Cadena, J. ;
Levine, D. J. ;
Angel, L. F. ;
Maxwell, P. R. ;
Brady, R. ;
Sanchez, J. F. ;
Michalek, J. E. ;
Levine, S. M. ;
Restrepo, M. I. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (09) :2085-2091
[3]   Antifungal prophylaxis during the early postoperative period of lung transplantation [J].
Calvo, V ;
Borro, JM ;
Morales, P ;
Morcillo, A ;
Vicente, R ;
Tarrazona, V ;
París, F .
CHEST, 1999, 115 (05) :1301-1304
[4]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[5]   A survey of anti-fungal management in lung transplantation [J].
Dummer, JS ;
Lazariashvilli, N ;
Barnes, J ;
Ninan, M ;
Milstone, AP .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (12) :1376-1381
[6]   Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study [J].
Gavalda, J ;
Len, O ;
Juan, RS ;
Aguado, JM ;
Fortun, J ;
Lumbreras, C ;
Moreno, A ;
Munoz, P ;
Blanes, M ;
Ramos, A ;
Rufi, G ;
Gurgui, M ;
Torre-Cisneros, J ;
Montejo, M ;
Cuenca-Estrella, M ;
Rodriguez-Tudela, JL ;
Pahissa, A .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :52-59
[7]  
Gordon S M, 2001, Transpl Infect Dis, V3, P161, DOI 10.1034/j.1399-3062.2001.003003161.x
[8]   Pre-emptive therapy with azoles in lung transplant patients [J].
Hamacher, J ;
Spiliopoulos, A ;
Kurt, AM ;
Nicod, LP .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (01) :180-186
[9]   Voriconazole prophylaxis in lung transplant recipients [J].
Husain, S. ;
Paterson, D. L. ;
Studer, S. ;
Pilewski, J. ;
Crespo, M. ;
Zaldonis, D. ;
Shutt, K. ;
Pakstis, D. L. ;
Zeevi, A. ;
Johnson, B. ;
Kwak, E. J. ;
McCurry, K. R. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (12) :3008-3016
[10]  
*JANSS PHARM, 2001, SPOR ITR PACK INS